Protagenic Therapeutics Profitability Analysis

PTIXW Stock  USD 0.01  0.00  0.00%   
Based on Protagenic Therapeutics' profitability indicators, Protagenic Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Protagenic Therapeutics' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
1995-09-30
Previous Quarter
-1.6 M
Current Value
-640.8 K
Quarterly Volatility
12 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Protagenic Therapeutics' Days Sales Outstanding is fairly stable compared to the past year. Days Of Sales Outstanding is likely to climb to 94.58 in 2024, whereas Price To Sales Ratio is likely to drop 0.28 in 2024. At this time, Protagenic Therapeutics' Net Interest Income is fairly stable compared to the past year. Income Quality is likely to climb to 0.95 in 2024, whereas Accumulated Other Comprehensive Income is likely to drop (119.2 K) in 2024.
For Protagenic Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Protagenic Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Protagenic Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Protagenic Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Protagenic Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets
(0.90)
Return On Equity
(2.06)
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Protagenic Therapeutics Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Protagenic Therapeutics's current stock value. Our valuation model uses many indicators to compare Protagenic Therapeutics value to that of its competitors to determine the firm's financial worth.
Protagenic Therapeutics is regarded second in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . At this time, Protagenic Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Protagenic Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Protagenic Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Protagenic Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
-2.06
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Protagenic Therapeutics

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.9
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Protagenic Return On Asset Comparison

Protagenic Therapeutics is currently under evaluation in return on asset category among its peers.

Protagenic Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Protagenic Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Protagenic Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Protagenic Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Protagenic Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-113.5 K-119.2 K
Operating Income-4.5 M-4.8 M
Income Before Tax-5 M-5.3 M
Total Other Income Expense Net-473.5 K-497.2 K
Net Loss-5 M-5.3 M
Income Tax Expense 2.00  1.90 
Interest Income303.2 K172.1 K
Net Loss-2.3 M-2.4 M
Net Interest Income176.5 K185.3 K
Net Loss-3.9 M-4.1 M
Net Loss(1.15)(1.21)
Income Quality 0.74  0.95 
Net Income Per E B T 0.91  0.76 

Protagenic Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Protagenic Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Protagenic Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Protagenic Therapeutics' important profitability drivers and their relationship over time.

Protagenic Therapeutics Profitability Trends

Protagenic Therapeutics profitability trend refers to the progression of profit or loss within a business. An upward trend means that Protagenic Therapeutics' profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is Protagenic Therapeutics' gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

Protagenic Therapeutics Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between Protagenic Therapeutics different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards Protagenic Therapeutics in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down Protagenic Therapeutics' future profitability.

Use Protagenic Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Protagenic Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protagenic Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Protagenic Therapeutics Pair Trading

Protagenic Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Protagenic Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Protagenic Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Protagenic Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Protagenic Therapeutics to buy it.
The correlation of Protagenic Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Protagenic Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Protagenic Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Protagenic Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Protagenic Therapeutics position

In addition to having Protagenic Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Climate Change Thematic Idea Now

Climate Change
Climate Change Theme
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.